首頁 > 市場調查報告書 > 製藥

疫苗癌症

市場調查報告書

商品編碼

1736515

全球子宮頸癌疫苗市場規模：按產品類型、分銷管道和地區分類的範圍和預測

Global Cervical Cancer Vaccine Market Size By Product Type (Gardasil, Gardasil 9, and Cervarix), By Distribution Channel (Hospitals, Government Entities, and Clinics), By Geography Scope And Forecast

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄

子宮頸癌疫苗市場規模及預測

2024 年子宮頸癌疫苗市場規模價值 50.8 億美元，預計到 2032 年將達到 144.8 億美元，在 2026-2032 年預測期內的複合年成長率為 13.94%。

女性子宮頸癌發生率的上升尤其令人擔憂，因為它是一種相當常見的癌症，並且可能是首要的死亡原因。子宮頸癌疫苗的市場驅動力是全球子宮頸癌盛行率的上升。全球特別是開發中國家宮頸癌患者數量的快速增加促使主要企業以低成本開發新疫苗。此外，子宮頸癌發生率的上升促使政府和非營利組織採取舉措提高人們對子宮頸癌控制和預防、人類乳突病毒(HPV)疫苗的認知。全球子宮頸癌疫苗市場報告對市場進行了全面評估。它全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及在市場中發揮關鍵作用的因素。

定義全球子宮頸癌疫苗市場

子宮頸癌是一種發生在女性子宮頸（子宮與陰道的開口）的癌症。子宮頸癌的早期症狀包括陰道異常出血，例如性交後或月經期間出血。大多數的子宮頸癌病例是由一種名為人類乳突病毒的常見病毒引起。大約99%的子宮頸癌是由高危險型人類乳突病毒（HPV）感染引起的。如果感染在子宮頸內持續存在，HPV會導致子宮頸組織異常生長。因此，疣狀組織的異常生長可能導致子宮頸癌。

子宮頸癌的治療包括手術、放射治療和化療。根據世界衛生組織 (WHO) 的數據，子宮頸癌是全球女性第四大常見癌症。然而，預防措施可以降低全球子宮頸癌病例增加的風險。子宮頸癌疫苗在預防導致女性子宮頸癌的 HPV 感染方面發揮重要作用。 HPV人類乳突病毒(HPV)疫苗有助於保護人體免受致癌的人類乳突病毒 (HPV) 感染。

如果在女孩和婦女感染病毒之前接種，該疫苗可以預防大多數子宮頸癌。世界衛生組織 (WHO) 建議 11 歲或 12 歲的女孩透過美國免疫計畫接種人類乳突病毒(HPV)疫苗。然而，該疫苗最早可以在 9 歲，即在發生任何性接觸或接觸 HPV 之前接種。根據美國疾病管制與預防中心 (CDC) 的建議，人類乳突病毒(HPV)疫苗建議接種兩劑，每劑間隔六個月。現在無需再遵循先前建議的三劑接種方案。

全球子宮頸癌疫苗市場概況

全球子宮頸癌病例不斷增加，這可能會增加對子宮頸癌疫苗的需求。根據美國癌症協會的數據，2021年將診斷出14,480例新的侵襲性子宮頸癌病例。此外，約有4,290名女性將死於子宮頸癌，而子宮頸癌歷來是美國女性癌症死亡的主要原因之一。子宮頸癌疫苗可提供針對HPV感染的終身特異性抗體。如果保護作用持久，且無需定期終身加強接種，子宮頸癌疫苗的有效性和可接受性將顯著提高。因此，疫苗的有效性至關重要。

研究表明，目前尚未發現任何人類乳突病毒(HPV)疫苗導致死亡的案例，但存在一些副作用。這些副作用雖然輕微，但有可能成為市場的主要限制因素。美國癌症協會指出，人類乳突病毒(HPV)疫苗可能會引起頭痛、發燒、噁心和頭暈。此外，在新興和低度開發國家建立國家疫苗接種計劃可以擴大全球子宮頸癌疫苗市場。

概述
北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 其他亞太地區
拉丁美洲
- 巴西
- 阿根廷
- 其他拉丁美洲
中東和非洲
- 阿拉伯聯合大公國
- 沙烏地阿拉伯
- 南非
- 其他中東和非洲地區

第8章全球子宮頸癌疫苗市場競爭格局

概述
各公司市場排名
公司地理分佈
公司產業佈局
ACE矩陣

第9章公司簡介

Merck & Co. Inc.
GlaxoSmithKline plc.
Sanofi
AstraZeneca PLC
Bristol

第10章已驗證的市場情報

關於已驗證的市場情報
動態資料視覺化

簡介目錄

Product Code: 37338

Cervical Cancer Vaccine Market Size And Forecast

Cervical Cancer Vaccine Market size was valued at USD 5.08 Billion in 2024, and the market size will reach USD 14.48 Billion by 2032, growing at a CAGR of 13.94% from 2026 to 2032.

The rising rate of cervical cancer among women is of particular concern because it may be a significantly common form of cancer and the number one reason for death. Its increasing prevalence worldwide is a major driver for the Cervical Cancer Vaccine Market. The worldwide surge in the number of cervical cancer patients, especially in developing countries, has motivated key players to develop new vaccines at a low cost. Furthermore, the growing incidence of cervical cancer has provoked governments and non-profit organizations to take the initiative to raise awareness regarding the control & prevention of cervical cancer and HPV vaccinations. The Global Cervical Cancer Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Cervical Cancer Vaccine Market Definition

Cervical cancer is a type of cancer that occurs in the cervix of the female body, at the opening of the womb from the vagina. The early symptoms of cervical cancer include unusual vaginal bleeding, such as bleeding after sex or between periods. Almost all cases of cervical cancer are caused by a very common virus called human papillomavirus. Around 99% of all cervical cancer caused due to infection with high-risk human papillomaviruses (HPV). HPV develops an abnormal growth of the tissue at the cervix if the infection stays inside the cervix for a long time. Thus, certain abnormal growth of the tissues such as warts can lead to cancer in the cervix.

Treatments for cervical cancer include surgery, radiotherapy, and chemotherapy. According to the World Health Organization, Cervical cancer is the fourth most common type of cancer in women around the world. However preventive measures can reduce the risk of increasing positive cases around the world. Cervical cancer vaccination plays a vital role in the prevention of the HPV infection that causes cervical cancer in women. The HPV vaccine helps to protect the body against infection with human papillomavirus or HPV that results in causing cancers.

The vaccine can prevent most cases of cervical cancer if given before a girl or woman is exposed to the virus. The World Health Organization has recommended the HPV vaccine for girls ages 11 or 12 through national immunization programs. However, the vaccine can be given as early as age 9 before they have sexual contact and are exposed to HPV. According to the Centers for Disease Control and Prevention (CDC), it is recommended that patients receive two doses of HPV vaccine at intervals of six months. Nowadays, taking a three-dose schedule as previously directed is unnecessary.

Global Cervical Cancer Vaccine Market Overview

Cervical cancer cases are increasing globally, which may increase the demand for cervical vaccines. According to the American Cancer Society, 14,480 new cases of invasive cervical cancer will be diagnosed in the United States in 2021. Furthermore, around 4,290 women will die from cervical cancer, which was historically one of the leading causes of cancer death in American women. The Cervical Cancer Vaccine ensures the persistence of particular antibodies against HPV infection for the rest of one's life. The effectiveness and acceptability of the Cervical Cancer Vaccine would be considerably enhanced if the protection was long-lasting and did not require regular boosters throughout life. As a result, the efficiency of the vaccine is critical.

Although investigations and research have found no deaths associated with any HPV vaccine, there are some side effects. These are minor, but they have the potential to become a major market constraint. According to the American Cancer Society, the HPV vaccine might cause headaches, fevers, nausea, and dizziness. Furthermore, the establishment of a national immunization program in developing and underdeveloped nations can expand the global Cervical Cancer Vaccine Market.

Global Cervical Cancer Vaccine Market: Segmentation Analysis

The Global Cervical Cancer Vaccine Market is segmented Based on Product Type, Distribution Channel, And Geography.

Cervical Cancer Vaccine Market, By Product Type

Gardasil
Gardasil 9
Cervarix

Based on Product Type, the market is bifurcated into Gardasil, Gardasil 9, and Cervarix. Gardasil accounted for the largest market share in 2020 and is projected to grow at a CAGR of 14.42% during the forecast period. Gardasil is a human papillomavirus (HPV) vaccine. It is a suspension for injection that contains purified proteins for four types of human papillomavirus (types 6, 11, 16, and 18). It is available in vials or prefilled syringes. Gardasil is used in males and females from the age of nine years to protect against the following conditions caused by specific types of human papillomavirus (HPV) such as precancerous lesions (growths) in the cervix, vulva or vagina and anus; cervical and anal cancers; genital warts.

Cervical Cancer Vaccine Market, By Application

Hospitals
Government Entities
Clinics

Based on the Application, the market has been segmented into Hospitals, Government Entities, and Clinics. Hospitals accounted for the largest market share in 2020 and are projected to grow at the highest CAGR of 14.65% during the forecast period. Government Entities was the second-largest market in 2020, and it is projected to grow at the highest CAGR.

Cervical Cancer Vaccine Market, By Geography

Asia Pacific
Middle East & Africa
Latin America

Based on Geography, the market is classified into Asia Pacific, Middle East & Africa, and Latin America. The Asia Pacific accounted for the largest market share and the Middle East & Africa was the second-largest market in 2020. Asia's economy continues to grow steadily, with strong progress in trading. The region is one of the leading and fastest-growing economies in the global market. The Asia Pacific region is likely to witness the highest growth in the global cervical cancer vaccine market over the forecast period owing to the extension of the already strong biologics market in the region, and the availability of screening tests and vaccine development potential as well.

Key Players

The "Global Cervical Cancer Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck & Co. Inc., GlaxoSmithKline plc., Sanofi, AstraZeneca PLC, Bristol, and Others.

The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

In February 2021, Merck acquired Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases.
In June 2021, Sanofi partnered with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor-positive breast cancer.

1 INTRODUCTION OF THE GLOBAL CERVICAL CANCER VACCINE MARKET

1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Assumptions
1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

2.1 Data Mining
2.2 Data Triangulation
2.3 Bottom-Up Approach
2.4 Top-Down Approach
2.5 Research Flow
2.6 Key Insights from Industry Experts
2.7 Data Sources

3 EXECUTIVE SUMMARY

3.1 Market Overview
3.2 Ecology Mapping
3.3 Absolute Market Opportunity
3.4 Market Attractiveness
3.5 Global Cervical Cancer Vaccine Market Geographical Analysis (CAGR %)
3.6 Global Cervical Cancer Vaccine Market, By Product Type (USD Million)
3.7 Global Cervical Cancer Vaccine Market, By Distribution Channel (USD Million)
3.8 Future Market Opportunities
3.9 Global Market Split
3.10 Product Life Line

4 GLOBAL CERVICAL CANCER VACCINE MARKET OUTLOOK

4.1 Global Aquaculture Vaccines Evolution
4.2 Drivers
- 4.2.1 Driver1
- 4.2.2 Driver 2
4.3 Restraints
- 4.3.1 Restraint1
- 4.3.2 Restraint 2
4.4 Opportunities
- 4.4.1 Opportunity1
- 4.4.2 Opportunity 2
4.5 Porters Five Force Model
4.6 Value Chain Analysis
4.7 Pricing Analysis
4.8 Macroeconomic Analysis

5 GLOBAL CERVICAL CANCER VACCINE MARKET, BY PRODUCT TYPE

5.1 Overview
5.2 Gardasil
5.3 Gardasil 9
5.4 Cervarix

6 GLOBAL CERVICAL CANCER VACCINE MARKET, BY APPLICATION

6.1 Overview
6.2 Hospitals
6.3 Government Entities
6.4 Clinics

7 GLOBAL CERVICAL CANCER VACCINE MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Italy
- 7.3.5 Spain
- 7.3.6 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Argentina
- 7.5.3 Rest of Latin America
7.6 Middle-East and Africa
- 7.6.1 UAE
- 7.6.2 Saudi Arabia
- 7.6.3 South Africa
- 7.6.4 Rest of Middle-East and Africa

8 GLOBAL CERVICAL CANCER VACCINE MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Developments
8.4 Company Regional Footprint
8.5 Company Industry Footprint
8.6 ACE Matrix

9 COMPANY PROFILES

9.1 Merck & Co. Inc.
- 9.1.1 Company Overview
- 9.1.2 Company Insights
- 9.1.3 Product Benchmarking
- 9.1.4 Key Development
- 9.1.5 Winning Imperatives
- 9.1.6 Current Focus & Strategies
- 9.1.7 Threat from Competition
- 9.1.8 SWOT Analysis
9.2 GlaxoSmithKline plc.
- 9.2.1 Company Overview
- 9.2.2 Company Insights
- 9.2.3 Product Benchmarking
- 9.2.4 Key Development
9.3 Sanofi
- 9.3.1 Company Overview
- 9.3.2 Company Insights
- 9.3.3 Product Benchmarking
- 9.3.4 Key Development
9.4 AstraZeneca PLC
- 9.4.1 Company Overview
- 9.4.2 Company Insights
- 9.4.3 Product Benchmarking
- 9.4.4 Key Development
9.5 Bristol
- 9.5.1 Company Overview
- 9.5.2 Company Insights
- 9.5.3 Product Benchmarking
- 9.5.4 Key Development